Scilex Holding Company (SCLXW) stock declined over -10.56%, trading at $0.16 on NASDAQ, down from the previous close of $0.18. The stock opened at $0.18, fluctuating between $0.14 and $0.19 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 02, 2026 | 0.17 | 0.18 | 0.15 | 0.18 | 5.01K |
| Jul 01, 2026 | 0.15 | 0.19 | 0.14 | 0.16 | 11.58K |
| Jun 30, 2026 | 0.12 | 0.13 | 0.08 | 0.13 | 17.35K |
| Jun 29, 2026 | 0.12 | 0.12 | 0.12 | 0.12 | 231 |
| Jun 26, 2026 | 0.13 | 0.13 | 0.12 | 0.12 | 1.01K |
| Jun 25, 2026 | 0.15 | 0.15 | 0.13 | 0.13 | 1.26K |
| Jun 24, 2026 | 0.19 | 0.19 | 0.19 | 0.19 | 5 |
| Jun 23, 2026 | 0.19 | 0.19 | 0.13 | 0.16 | 150 |
| Jun 22, 2026 | 0.13 | 0.14 | 0.13 | 0.14 | 12 |
| Jun 18, 2026 | 0.16 | 0.16 | 0.13 | 0.13 | 81 |
| Jun 17, 2026 | 0.17 | 0.17 | 0.15 | 0.17 | 1.66K |
| Jun 16, 2026 | 0.21 | 0.21 | 0.17 | 0.17 | 2.22K |
| Jun 15, 2026 | 0.19 | 0.21 | 0.19 | 0.21 | 721 |
| Jun 12, 2026 | 0.17 | 0.17 | 0.17 | 0.17 | 575 |
| Jun 11, 2026 | 0.17 | 0.17 | 0.17 | 0.17 | 4.28K |
| Jun 10, 2026 | 0.14 | 0.17 | 0.14 | 0.17 | 5.72K |
| Jun 09, 2026 | 0.14 | 0.14 | 0.14 | 0.14 | 1.51K |
| Jun 08, 2026 | 0.17 | 0.17 | 0.15 | 0.15 | 706 |
| Jun 04, 2026 | 0.16 | 0.16 | 0.16 | 0.16 | 41 |
| Jun 03, 2026 | 0.17 | 0.17 | 0.14 | 0.14 | 390 |
Scilex Holding Company operates as a biopharmaceutical firm primarily engaged in creating and distributing non-opioid treatments for individuals suffering from acute and chronic pain conditions. Its flagship product, ZTlido 1.8%, is a prescription-only topical lidocaine formulation designed to alleviate neuropathic pain, specifically that associated with post-herpetic neuralgia, a type of nerve pain occurring after a shingles infection. The company's development pipeline also features SP-102, known as SEMDEXA, a viscous corticosteroid gel administered via epidural injections. This candidate is currently in Phase 3 clinical trials, targeting lumbosacral radicular pain. Another investigational drug, SP-103, aims to treat low back pain and is progressing through Phase 2 clinical trials. Additionally, SP-104, an innovative low-dose, delayed-release naltrexone hydrochloride formulation, is in Phase 1 clinical development for managing fibromyalgia. Scilex Holding Company is headquartered in Palo Alto, California, and functions as a subsidiary of Sorrento Therapeutics, Inc.
| Employees | 115 |
| Beta | 1.71 |
| Sales or Revenue | $46.74M |
| 5Y Sales Change% | 1.407% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep